Table 2.

Cardiovascular outcome trials completed in 2020: comparison of active vs. placebo group

VERTIS-CV [23]		SCORED [28]
Class & cardiovascular outcomes	HR (95.6% CI) p-value	Class & cardiovascular outcomes	HR (95.6% CI) p-value
Primary composite outcome Composite outcome of MACE (CV death, nonfatal MI, nonfatal stroke)	0.97 (0.85–1.11) p < 0.001	Primary composite outcome Total occurrences of CV death, HHF, and urgent visits for HF	0.74 (0.63–0.88) p < 0.001
Secondary outcome CV death or HHF	0.88 (0.75–1.03) p = 0.11	Secondary outcome Total occurrence of HF events	0.67 (0.55–0.82) p < 0.001
Secondary outcome CV death	0.92 (0.77–1.11) p = 0.39	Secondary outcome CV death	0.90 (0.73–1.12) p = 0.35
Secondary outcome Hospitalization for heart failure	0.70 (0.54–0.90) p = 0.006	Secondary outcome 3P-Mace and HHF events	0.72 (0.63–0.83)
Secondary outcome Kidney composite: dialysis/transplant, doubling of serum creatinine level, or renal death	0.81 (0.63–1.04) p = 0.08	Secondary outcome All-cause mortality	0.99 (0.83–1.18)

Adverse events	Event rate (%) active vs. placebo group	Adverse events	Event rate (%) active vs. placebo group
Urinary tract infection	12.2 vs. 12.0 vs. 10.2	Diarrhea	8.5 vs. 6.0
Acute pancreatitis	0.4 vs. 0.2 vs. 0.4	Genital infections	2.4 vs. 0.9
Diabetic ketoacidosis	0.3 vs. 0.4 vs. 0.1	Diabetic ketoacidosis	0.6 vs. 0.3